• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sagaliam Acquisition Corp. (Amendment)

    2/14/23 4:47:25 PM ET
    $SAGA
    Blank Checks
    Finance
    Get the next $SAGA alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

     

    Sagaliam Acquisition Corporation

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001

    (Title of Class of Securities)

     

    78661R205

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 78661R205  

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    ATW SPAC MANAGEMENT LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    120,000*

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    120,000*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    120,000*

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.00%*

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IA, OO

     

     

     

     

    CUSIP No. 78661R205  

     

    1.

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Antonio Ruiz-Gimenez

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a) ☐

    (b) ☒

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Spain

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    120,000*

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    120,000*

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    120,000*

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (see instructions) ☐

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    1.00%*

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    IN, HC

     

     

     

     

    Item 1.

     

      (a)

    Name of Issuer

    Sagaliam Acquisition Corporation (the “Issuer”)

         
      (b)

    Address of Issuer’s Principal Executive Offices

    11835 W. Olympic Blvd, Suite 1150

    Los Angeles CA 90064

     

    Item 2.

     

      (a)

    Name of Person Filing:

    ATW SPAC Management LLC*

    Antonio Ruiz-Gimenez*

         
      (b)

    Address of the Principal Office or, if none, residence

    17 State Street, Suite 2100

    New York, New York 10004

         
      (c)

    Citizenship

    ATW SPAC Management LLC – Delaware

    Antonio Ruiz-Gimenez – Spain

         
      (d)

    Title of Class of Securities

    Class A Common Stock

         
      (e)

    CUSIP Number

    78661R205

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    ATW SPAC Management LLC:

     

      (a) ☐ Broker or Dealer Registered Under Section 15 of the Act (15 U.S.C. 78o)
      (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c)
      (c) ☐ Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c)
      (d) ☐ Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8)
      (e) ☒ Investment Adviser in accordance with § 240.13d-1(b)(1)(ii)(E)
      (f) ☐ Employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F)
      (g) ☐ Parent Holding Company or control person in accordance with §240.13d-1(b)(ii)(G)
      (h) ☐ Savings Association as defined in §3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813)
      (i) ☐ Church plan that is excluded from the definition of an investment company under §3(c)(15) of the Investment Company Act of 1940 (15 U.S.C. 80a-3)
      (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J)
      (k) ☐ Group, in accordance with §240.13d-1(b)(ii)(K) (a) [_]

     

    Item 4. Ownership.

     

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a)

    Amount beneficially owned:

    ATW SPAC Management LLC – 120,000*

    Antonio Ruiz-Gimenez – 120,000*

           
      (b)

    Percent of class:

    ATW SPAC Management LLC – 1.00%*

    Antonio Ruiz-Gimenez – 1.00%*

     

     

     

     

      (c) Number of shares as to which the person has:
           
        (i)

    Sole power to vote or to direct the vote

    ATW SPAC Management LLC – 0

    Antonio Ruiz-Gimenez – 0

           
        (ii)

    Shared power to vote or to direct the vote

    ATW SPAC Management LLC – 120,000*

    Antonio Ruiz-Gimenez – 120,000*

           
        (iii)

    Sole power to dispose or to direct the disposition of

    ATW SPAC Management LLC – 0

    Antonio Ruiz-Gimenez – 0

           
        (iv)

    Shared power to dispose or to direct the disposition of

    ATW SPAC Management LLC – 120,000*

    Antonio Ruiz-Gimenez – 120,000*

     

    Instruction. For computations regarding securities which represent a right to acquire an underlying security see §240.13d-3(d)(1).

     

     

    * The Class A Common Stock (the “Shares”) of the Issuer are held by one or more private funds managed by ATW SPAC Management LLC, a Delaware limited liability company (the “Adviser”), which has been delegated exclusive authority to vote and/or direct the disposition of such Shares held by sub-accounts of one or more pooled investment vehicles (the “Funds”) managed by a Delaware limited liability company. Antonio Ruiz-Gimenez is a Managing Member of the Adviser. For the purposes of Reg. Section 240.13d-3, the reporting persons herein may be deemed to beneficially own an aggregate of 120,000 Shares, or 1.00%, of the 12,015,000 Shares issued and outstanding as of November 14, 2022, as disclosed in the Issuer’s Form 10-Q filed with the SEC on November 14, 2022.

     

    This report shall not be deemed an admission that any reporting person or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein.

     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

     

    Instruction. Dissolution of a group requires a response to this item.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    N/A

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    N/A

     

    Item 8. Identification and Classification of Members of the Group.

     

    N/A

     

    Item 9. Notice of Dissolution of Group.

     

    N/A

     

    Item 10. Certification.

     

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 78661R205

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

      ATW SPAC Management LLC
         
      By:

    /s/ Antonio Ruiz-Gimenez

        Antonio Ruiz-Gimenez, Managing Member
         
      Antonio Ruiz-Gimenez
         
      By: /s/ Antonio Ruiz-Gimenez
        Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

     

    CUSIP No. 78661R205

     

    JOINT FILING STATEMENT

    PURSUANT TO RULE 13D-1(K)(1)

     

    The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Shares held in the form of units of Sagaliam Acquisition Corporation together with any or all amendments thereto, when and if required. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.

     

    This Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.

     

    Dated: February 14, 2023

     

      ATW SPAC Management LLC
         
      By:

    /s/ Antonio Ruiz-Gimenez

        Antonio Ruiz-Gimenez, Managing Member
         
      Antonio Ruiz-Gimenez
         
      By: /s/ Antonio Ruiz-Gimenez
        Individually

     

     

     

    Get the next $SAGA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SAGA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SAGA
    SEC Filings

    View All

    SEC Form 25-NSE filed by Sagaliam Acquisition Corp.

    25-NSE - Sagaliam Acquisition Corp (0001855351) (Subject)

    4/9/24 10:30:08 AM ET
    $SAGA
    Blank Checks
    Finance

    Sagaliam Acquisition Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Financial Statements and Exhibits

    8-K - Sagaliam Acquisition Corp (0001855351) (Filer)

    3/7/24 9:38:34 AM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form 10-Q filed by Sagaliam Acquisition Corp.

    10-Q - Sagaliam Acquisition Corp (0001855351) (Filer)

    3/6/24 9:45:42 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sagaliam Acquisition Corp Launches Improved IPF Formula with Vitamin C in Pill and Lozenge Form and Addition of New Slimming Neutraceutical

    BAYTOWN, TX / ACCESSWIRE / May 1, 2024 / Sagaliam Acquisition Corp ("SAGA", the "Company") (NASDAQ:SAGA) announced today that Virogentics, Inc., a wholly owned subsidiary of SAGA ("VIRO"), and the Bulgarian product development team, headed by Dr. Lachezar Ivanov and Harry Zhabilov, CSO, have developed a new IPF formula which combines a Vitamin C component with the existing patented compound. This product will be marketed as IPF Immune+ with Vit C. In addition, this new product will be available in both pill and lozenge form providing convenience and a more effective delivery for the users. The team has also begun production of a new slimming formula which will be added to the VIRO nutraceuti

    5/1/24 8:30:00 AM ET
    $SAGA
    Blank Checks
    Finance

    Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.

    NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

    4/26/24 8:00:00 AM ET
    $SAGA
    Blank Checks
    Finance

    SAGALIAM ACQUISITION CORP. ANNOUNCES DELISTING OF COMMON SHARES FROM NASDAQ

    New York, NY, March 07, 2024 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", SAGAR") (the "Company") received a Nasdaq Hearing Withdrawal letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on March 6, 2024. On May 26, 2023, Staff notified the Company that the market value of its listed securities had been below the minimum $50,000,000 required for continued listing as set forth in Listing Rule 5450(b)(2)(A) for the previous 30 consecutive trading days.1 Therefore, in accordance with Listing Rule 5810(c)(3)(C), the Company was provided 180 calendar days, or until November 22, 2023 to regain compliance with the Rule. O

    3/7/24 9:35:00 AM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Gld Sponsor Member, Llc

    3 - Sagaliam Acquisition Corp (0001855351) (Issuer)

    5/11/23 1:10:06 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Sagaliam Acquisition Corp. (Amendment)

    SC 13G/A - Sagaliam Acquisition Corp (0001855351) (Subject)

    2/14/24 1:49:11 PM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form SC 13G filed by Sagaliam Acquisition Corp.

    SC 13G - Sagaliam Acquisition Corp (0001855351) (Subject)

    2/14/24 12:16:06 PM ET
    $SAGA
    Blank Checks
    Finance

    SEC Form SC 13D filed by Sagaliam Acquisition Corp.

    SC 13D - Sagaliam Acquisition Corp (0001855351) (Subject)

    5/11/23 1:08:27 PM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Financials

    Live finance-specific insights

    View All

    Sagaliam Acquisition Corp. Announces Novation Agreement with Enzolytics, Inc.

    NEW YORK, NY / ACCESSWIRE / April 26, 2024 / Sagaliam Acquisition Corp. ("SAGAU", "SAGA", SAGAR") (the "Company") announced that Sagaliam entered into a Novation Agreement with Enzolytics, Inc. (OTC:ENZC), Biogenysis, Inc. (BGEN), and Virogentics, Inc. (VIRO) (together the "Parties"). ​Under this restructured agreement SAGA retains 100% ownership of VIRO, ITV-1, the nutraceutical products and license along with VIRO's other assets. This agreement transferred ownership of Biogenysis, Inc. ("BGEN") and it's IP, patents and associated asset being developed back to ENZC in exchange for a reduction of the price from $450,000,000 to $290,000,000 with the dividend of the purchase shares to come dir

    4/26/24 8:00:00 AM ET
    $SAGA
    Blank Checks
    Finance

    Enzolytics, Inc. Files Amended December 31, 2022 OTC Report with Audited Financials and Unaudited September 30, 2023 Quarterly Disclosure

    Provides Updates on SAGA Transaction and on Virogentics, Inc. and Biogenysis, Inc. ProgressALLEN, TX / ACCESSWIRE / November 20, 2023 / Enzolytics, Inc. (OTC:ENZC) (https://enzolytics.com/"https://enzolytics.com/). Enzolytics, Inc. (the "Company") filed an amended December 31, 2022 OTC Annual Report and its delinquent September 30, 2023 OTC quarterly disclosure. The purpose of the amended OTC Annual Report filed today is to include the audited financial statements for December 31, 2022 and 2021. As part of the recently completed sale of the two operating subsidiaries, Virogenetics, Inc. ("VIRO") and Biogenysis, Inc. ("BGEN"), to Sagaliam Acquisition Corp. (NASDAQ:SAGA)("SAGA") post-closing d

    11/20/23 9:10:00 AM ET
    $SAGA
    Blank Checks
    Finance

    $SAGA
    Leadership Updates

    Live Leadership Updates

    View All

    SAGALIAM ACQUISITION CORP. ANNOUNCES RECEIPT OF NASDAQ LISTING DELINQUENCY LETTER AND APPOINTMENT OF INDEPENDENT DIRECTORS

    New York, NY, July 28, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that it received a delinquency notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on July 25, 2023 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 (the "Form 10-Q"). Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commissio

    7/28/23 5:00:00 PM ET
    $SAGA
    Blank Checks
    Finance

    SAGALIAM ACQUISITION CORP. ANNOUNCES RESIGNATION OF THOMAS W. NEUKRANZ AS CHIEF FINANCIAL OFFICER AND DIRECTOR

    New York, NY, May 11, 2023 (GLOBE NEWSWIRE) -- Sagaliam Acquisition Corp. (NASDAQ: "SAGAU", "SAGA", "SAGAR") ("we", "us", "our", or the "Company") announced today that Thomas W. Neukranz, its Chief Financial Officer and member of its Board of Directors had resigned effective May 7, 2023. There were no disagreements between the Company and Mr. Neukranz on any matter related to the Company's operations, financial reporting, policies or practices. About Sagaliam Acquisition Corp. We are a blank check company incorporated under the laws of the State of Delaware on March 31, 2021 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganizati

    5/11/23 1:01:00 PM ET
    $SAGA
    Blank Checks
    Finance